Last updated: August 31, 2026
Repotrectinib, marketed by Bristol Myers Squibb as Augtyro, is a targeted tyrosine kinase inhibitor for ROS1-positive metastatic non-small-cell lung cancer (NSCLC). The drug entered the U.S. market in November 2023 with a differentiated profile: activity against ROS1 resistance mutations, including G2032R, and strong central nervous system penetration. U.S. sales increased from approximately $6 million in launch-quarter revenue in 2023 to about $170 million in 2024, according to Bristol Myers Squibb’s reported product sales.[1]
The commercial opportunity is concentrated but attractive. Repotrectinib competes in a biomarker-defined market with a limited patient population, high treatment value, and substantial unmet need after resistance to earlier ROS1 inhibitors. Its financial trajectory depends on first-line adoption, duration of therapy, CNS efficacy, diagnostic testing rates, competition from entrectinib and lorlatinib, and the timing of next-generation ROS1 inhibitors.
What is repotrectinib approved to treat?
Repotrectinib is FDA-approved for adults with locally advanced or metastatic ROS1-positive NSCLC.[2] The approval covers patients who are treatment-naive and those who received prior ROS1 tyrosine kinase inhibitor therapy.
The drug is not approved in the United States as a tumor-agnostic NTRK therapy, although its development program includes activity against TRKA, TRKB, and TRKC alterations. The commercial U.S. label is therefore narrower than the drug’s kinase profile.
FDA regulatory milestones
| Milestone |
Date |
| New Drug Application accepted by FDA |
2023 |
| FDA approval for ROS1-positive metastatic NSCLC |
November 15, 2023 |
| Brand name |
Augtyro |
| Active ingredient |
Repotrectinib |
| Sponsor at approval |
Turning Point Therapeutics |
| Current commercial owner |
Bristol Myers Squibb |
| FDA pathway |
Standard approval based primarily on TRIDENT-1 |
Bristol Myers Squibb acquired Turning Point Therapeutics in 2022 for approximately $4.1 billion, giving BMS control of repotrectinib before regulatory approval.[3]
How effective is repotrectinib in ROS1-positive lung cancer?
Repotrectinib’s principal commercial advantage is its activity after prior ROS1 inhibitor treatment, particularly where resistance is driven by solvent-front mutations. The TRIDENT-1 study reported an objective response rate of approximately 79% in treatment-naive patients and 38% in patients previously treated with a ROS1 tyrosine kinase inhibitor and chemotherapy.[4]
Repotrectinib also demonstrated intracranial activity, which is commercially important because brain metastases are common in ROS1-positive NSCLC and can drive treatment switching.
| TRIDENT-1 population |
Objective response rate |
Commercial relevance |
| ROS1 TKI-naive patients |
Approximately 79% |
Supports first-line use |
| Previously treated with ROS1 TKI and chemotherapy |
Approximately 38% |
Supports sequencing after resistance |
| ROS1 resistance mutation, including G2032R |
Clinically meaningful responses |
Differentiates from older agents |
| Patients with brain metastases |
Intracranial responses reported |
Supports CNS-driven prescribing |
The treatment value is highest in patients whose disease has developed resistance to crizotinib or entrectinib. Repotrectinib’s positioning in first-line treatment is more competitive because prescribers can choose between multiple ROS1-directed agents with established efficacy.
How large is the repotrectinib market?
The ROS1-positive segment represents roughly 1% to 2% of NSCLC cases. Because NSCLC remains a large cancer market, the absolute patient count is sufficient to support a substantial specialty-oncology product, but not a mass-market franchise.
The commercial market has four limiting factors:
- ROS1-positive disease is rare.
- Molecular testing is required before treatment.
- Patients may remain on therapy for several years.
- Competing targeted agents are already available.
The market is also expandable. Broader adoption of comprehensive genomic profiling can identify patients who would otherwise receive nonspecific chemotherapy or immunotherapy. ROS1 testing rates, liquid biopsy use, and guideline compliance directly affect the eligible population.
Estimated commercial drivers
| Driver |
Effect on Augtyro |
| First-line ROS1 use |
Increases patient duration and total revenue per patient |
| Post-crizotinib use |
Supports differentiated rescue therapy |
| CNS metastases |
Favors a CNS-penetrant product |
| G2032R resistance |
Creates a niche with fewer effective alternatives |
| Molecular testing |
Expands diagnosis and treatment initiation |
| Long treatment duration |
Raises revenue per treated patient |
| Generic crizotinib |
Lowers the cost of competing first-line therapy |
| New ROS1 inhibitors |
Creates future share and pricing pressure |
What were repotrectinib’s sales in 2023 and 2024?
Bristol Myers Squibb reported approximately $6 million in Augtyro sales during 2023 and about $170 million in 2024.[1] The 2024 result indicates rapid uptake after launch, although it remains below the revenue scale of BMS’s large immuno-oncology products.
| Year |
Reported Augtyro sales |
Interpretation |
| 2023 |
Approximately $6 million |
Initial U.S. launch period |
| 2024 |
Approximately $170 million |
Early commercial ramp |
| 2025 onward |
Dependent on label expansion and share gains |
Key valuation period |
The increase reflects formulary access, oncology-account penetration, physician familiarity, and use in patients with prior ROS1 inhibitor exposure. The first full year of sales is more informative than launch-quarter revenue because specialty drugs often require molecular testing, referral to thoracic oncology centers, and prior-authorization processing.
BMS does not disclose Augtyro as a separate operating segment with a full public cost structure. Gross-to-net deductions, patient-support programs, rebates, manufacturing costs, and sales-force expenses therefore limit direct assessment of product profitability.
What is the long-term revenue trajectory for repotrectinib?
The base case is a specialty oncology product with potential for several hundred million dollars in annual sales if it establishes itself as a preferred first-line and post-progression ROS1 therapy. A billion-dollar outcome would require broader patient capture, durable first-line use, strong international uptake, or additional approved indications.
Revenue scenario
| Scenario |
Commercial conditions |
Potential outcome |
| Downside |
First-line share remains limited; competitors retain preference; new ROS1 agents launch successfully |
Low-to-mid hundreds of millions in annual sales |
| Base case |
Strong first-line adoption, post-crizotinib use, and sustained CNS differentiation |
Several hundred million dollars annually |
| Upside |
Broad global uptake, durable treatment, label expansion, and limited competitive erosion |
Potential blockbuster-scale revenue |
Repotrectinib’s revenue per patient can be substantial because targeted NSCLC treatment often continues until disease progression or unacceptable toxicity. The key financial question is not only the number of new patients treated but also the duration of treatment and the proportion of patients retained through multiple lines.
How does repotrectinib compare with competing ROS1 drugs?
Repotrectinib competes primarily with crizotinib, entrectinib, and lorlatinib.
| Drug |
Company |
Main commercial position |
Key strength |
Key limitation |
| Repotrectinib |
Bristol Myers Squibb |
First-line and previously treated ROS1 NSCLC |
CNS penetration and resistance mutation activity |
Newer product with limited real-world history |
| Crizotinib |
Pfizer and generics |
Established ROS1 therapy |
Long clinical history and lower-cost generic access |
Weaker CNS durability and resistance profile |
| Entrectinib |
Roche |
ROS1 NSCLC with CNS activity |
Broad ROS1 and NTRK development history |
Competitive efficacy and tolerability pressure |
| Lorlatinib |
Pfizer |
ROS1 and ALK-directed therapy |
Potent CNS activity |
Adverse-event management and competing indications |
Repotrectinib’s strongest competitive argument is sequencing after a prior ROS1 inhibitor. Its first-line argument depends on whether physicians prioritize resistance coverage and CNS control over familiarity, price, or established guideline positioning.
Lorlatinib is a significant clinical competitor because it has high CNS activity and a broad molecular profile. Entrectinib has earlier market entry and established treatment experience. Generic crizotinib can influence payer decisions, particularly in treatment-naive patients.
What patent and exclusivity protections cover repotrectinib?
Repotrectinib benefits from regulatory exclusivity, patent protection, and formulation and method-of-use claims. The principal protection is directed to the small-molecule compound and related therapeutic uses, while secondary claims may cover dosage forms, treatment of kinase-driven cancers, resistance mutations, and administration methods.
Regulatory exclusivity
Repotrectinib received five-year new chemical entity exclusivity in the United States, generally extending to November 2028. FDA approval occurred on November 15, 2023.[2] A six-month pediatric exclusivity extension could extend relevant protection if qualifying pediatric studies are completed and accepted.
NCE exclusivity prevents FDA approval of an abbreviated new drug application that relies on the active ingredient during the exclusivity period. It does not prevent a competitor from filing a full 505(b)(2) application or from challenging patents.
Patent position
The commercial patent estate is expected to extend beyond the NCE period through compound, treatment, formulation, and related patent claims. The effective generic-entry date will depend on:
- The patents listed in the FDA Orange Book.
- Any Paragraph IV certifications.
- Patent-term adjustment or patent-term extension.
- The outcome of infringement litigation.
- The scope of claims surviving validity challenges.
- The availability of non-infringing manufacturing routes.
The Orange Book should be evaluated patent by patent rather than through a single headline expiration date. Compound claims generally provide the strongest protection. Formulation and method-of-use claims can delay some ANDA launches but are more vulnerable to design-around strategies or claim-construction disputes.
No broad biosimilar risk exists because repotrectinib is a small molecule, not a biologic. The relevant future entrants are generic or 505(b)(2) products.
When does repotrectinib lose exclusivity?
The earliest statutory U.S. exclusivity milestone is November 2028, based on five-year NCE exclusivity. Commercial generic entry is likely to depend on patent expiry and litigation rather than NCE exclusivity alone.
| Protection |
Expected timing or role |
| Five-year NCE exclusivity |
Through approximately November 2028 |
| Pediatric exclusivity |
Possible six-month extension if awarded |
| Compound patents |
Potentially extend beyond regulatory exclusivity |
| Formulation patents |
May provide additional, narrower protection |
| Method-of-use patents |
Can protect labeled indications or treatment populations |
| Generic entry |
Dependent on ANDA timing, certifications, and litigation |
A generic could seek approval for an indication that avoids a patented method of use, subject to FDA labeling rules and patent scope. This creates a potential “skinny label” pathway if core compound protection has expired or is invalidated.
Are there Paragraph IV challenges or patent lawsuits against Augtyro?
The principal litigation risk is a future ANDA Paragraph IV challenge after generic applicants can file an abbreviated application. Publicly reported Augtyro litigation was limited during the early post-launch period through 2024. The absence of an early challenge is consistent with a recently approved product that still has NCE exclusivity and an unseasoned commercial market.
A Paragraph IV case would determine whether the asserted patent claims are valid, enforceable, and infringed. A settlement could establish an agreed generic launch date before patent expiry, subject to antitrust and regulatory review.
The most relevant litigation targets would be:
- Compound patents covering repotrectinib.
- Patents covering treatment of ROS1-positive cancer.
- Patents directed to resistant ROS1 mutations.
- Formulation patents covering commercial capsule products.
What manufacturing and intellectual-property barriers affect generic entry?
Repotrectinib is a complex synthetic small molecule with stereochemical and process-control requirements. Generic manufacturers would need to demonstrate pharmaceutical equivalence, bioequivalence, impurity control, and consistent solid-state or formulation characteristics.
Manufacturing barriers are unlikely to create durable protection by themselves if the active ingredient and formulation can be reproduced through an alternative process. They can, however, increase development cost and delay entry, particularly where process patents, formulation claims, or analytical complexity are involved.
The strongest barrier remains the composition-of-matter patent estate. Process patents are secondary unless they cover the only commercially practical route or a route required to meet purity and yield specifications.
What geographic markets matter for repotrectinib?
The United States is the core initial market because of high oncology pricing, concentrated thoracic-oncology prescribing, and rapid uptake of molecularly targeted therapy. Europe and Japan add volume but generally produce lower net prices and slower reimbursement decisions.
International performance depends on:
- Country-specific regulatory approvals.
- ROS1 testing availability.
- Reimbursement for precision oncology.
- Local competition from crizotinib and entrectinib.
- BMS’s commercial infrastructure.
- Use of companion or next-generation sequencing diagnostics.
The product’s value is highest in countries with routine genomic testing and reimbursement for targeted NSCLC therapies.
Which companies are challenging repotrectinib commercially?
Bristol Myers Squibb faces competition from established pharmaceutical companies rather than a single dominant generic threat.
Roche competes through entrectinib. Pfizer competes with crizotinib and lorlatinib. Future ROS1 inhibitors, including agents designed for solvent-front resistance and CNS disease, could challenge repotrectinib’s differentiation before patent expiry.
The competitive landscape is shifting from first-generation ROS1 inhibition toward mutation-specific sequencing. Products that demonstrate activity against compound resistance mutations, maintain CNS control, and avoid dose-limiting neurologic or metabolic toxicity could take share from Augtyro.
Key Takeaways
- Repotrectinib is a targeted ROS1 therapy marketed by Bristol Myers Squibb as Augtyro.
- FDA approval covers locally advanced or metastatic ROS1-positive NSCLC.
- Reported sales rose from approximately $6 million in 2023 to about $170 million in 2024.
- CNS penetration and activity against resistance mutations are the drug’s main commercial differentiators.
- The addressable market is small but supports high revenue per patient and long treatment duration.
- NCE exclusivity generally runs through November 2028, with patents potentially extending beyond that date.
- Generic, not biosimilar, competition is the relevant post-exclusivity risk.
- The principal commercial threats are entrectinib, lorlatinib, generic crizotinib, and future next-generation ROS1 inhibitors.
- A base-case trajectory is several hundred million dollars in annual sales, with blockbuster potential requiring broader market capture or label expansion.
FAQs About Repotrectinib Market and Exclusivity
Is repotrectinib a blockbuster drug?
Repotrectinib has blockbuster potential but is not guaranteed to reach $1 billion in annual sales. Its market is constrained by the low prevalence of ROS1-positive NSCLC and competition from other targeted therapies.
What is the price of Augtyro in the United States?
Augtyro launched at an annualized list-price level of roughly $240,000, based on a reported monthly wholesale acquisition cost near $20,000. Net pricing is lower after rebates, discounts, and patient-support programs.
Does repotrectinib treat NTRK-positive cancer?
Repotrectinib inhibits TRK proteins and has NTRK-directed clinical activity, but its U.S. FDA approval is for ROS1-positive NSCLC. Larotrectinib and entrectinib are the principal U.S. tumor-agnostic NTRK competitors.
What is the main resistance mutation targeted by repotrectinib?
G2032R is the best-known ROS1 solvent-front resistance mutation targeted by repotrectinib. Activity against this mutation is central to its post-crizotinib positioning.
Could generic repotrectinib launch before 2028?
An ANDA applicant may prepare and submit a filing subject to applicable regulatory rules, but approval and commercial launch are constrained by NCE exclusivity and any enforceable patents. An earlier launch would generally require a successful patent challenge, settlement, or non-infringing regulatory pathway.
References
-
Bristol Myers Squibb. (2025). 2024 annual report. Bristol Myers Squibb Company.
-
U.S. Food and Drug Administration. (2023, November 15). FDA approves repotrectinib for ROS1-positive metastatic non-small cell lung cancer. https://www.fda.gov
-
Bristol Myers Squibb. (2022, August 17). Bristol Myers Squibb completes acquisition of Turning Point Therapeutics. Bristol Myers Squibb Company.
-
Drilon, A., Camidge, D. R., Lin, J. J., et al. (2024). Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. New England Journal of Medicine, 390, 118-131.